You are here

Late molecular recurrences in patients with chronic myeloid leukemia experiencing treatment-free remission

Key Points

  • Late molecular recurrences after 2 years in patients with CML experiencing TFR represent 14% of all molecular recurrences.
  • Patients with fluctuating minimal residual disease measurements during TFR are at high risk of late molecular recurrences.